Pharmacogenomics in cancer treatment

Author(s): Dr. Louise Vacca

Cancer pharmacogenomics has made several significant contributions to current cancer treatment, altering the treatment decision-making paradigm. Both somatic and germline mutations are used to better understand the underlying biology of cancer growth and treatment response. The level of evidence required to fully translate pharmacogenomic discoveries into the clinic has relied heavily on randomised control trials. The use of observational studies, as well as adaptive trials and next generation sequencing, to develop the required level of evidence for clinical implementation, is discussed in this review.